BIOTHERAPY DURING CHRONIC INFLAMMATORY BOWEL DISEASE: AN OVER-RISK OF TUBERCULOSIS REACTIVATION?

Anti-TNFα have revolutionized the management of chronic inflammatory rheumatic and intestinal diseases however, they are at high risk of reactivation of latent tuberculosis. These are most often extra-pulmonary tuberculosis and disseminated forms which occur during the first year and which can be avoided by screening and prophylactic treatment. The aim of this publication is to describe the epidemiological, clinical, biological, radiological and evolving data of patients having triggered tuberculosis under anti TNFα treatment followed at the Hassan II hospital center (CHU) in Fez during the period between January 2012 and January 2021. During this period, we collected 130 patients under anti TNF alpha of which 84.5% of patients are on Infliximab 15.5% on Adalimumab. Active tuberculosis occurred in 4.6% of patients whose mean age is 35.5 years and the sex ration is 5H / 1F. The duration of onset is on average after 5 sessions of anti TNF alpha. A phtysio assessment was carried out in all our patients before starting the anti TNF α, 2 of which were IDR positive completed by quantifying it which came back positive in a single patient.